A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
Purpose
Category
Child Health
IRB Number
20210408HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
-
Study Contact
Principal Investigator
Michael Odom
Eligibility
Eligible Ages
Eligible Genders
Accepts Healthy Volunteers
No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups